Clinical & Experimental Metastasis

, Volume 8, Issue 4, pp 345–359 | Cite as

Therapeutic efficacy of two different cytostatic-linked phosphonates in combination with razoxane in the transplantable osteosarcoma of the rat

  • T. Klenner
  • F. Wingen
  • B. Keppler
  • P. Valenzuela-Paz
  • F. Amelung
  • D. Schmähl


Two new compounds, 4-[4-[bis-(2-chloroethyl)-amino-]phenyl]-1-hydroxybutane-1,1-bisphosphonic acid (BAD) and aminotris-(methylenephosphonato)diamminoplatinum(ii) (ADP) that both have cytostatic and osteotropic properties, have shown good therapeutic efficacy against an osteosarcoma which metastasizes and kills by lung metastases. We therefore combined each of these drugs with the antimetastatic agent razoxane. Razoxane (20 mg/kg i.p., 5 days/week for 6 weeks) was administered in combination with either BAD (30 mg/kg i.p.) or ADP (37·5 mg/kg i.v.) twice weekly for 3 weeks. Tumour volumes, body weight, survival time and occurrence of metastases were recorded, in addition to the measurement of the metastasis area compared to the total lung area in serial histological lung samples. In both experiments, razoxane effected a significant increase in life span while being ineffective in tumour inhibition. Razoxane in combination with BAD displayed an enhanced anticancer activity which was not significant. ADP had a good antineoplastic activity and a large increase in survival time (144 per cent I LS). Razoxane used in combination with ADP did not influence antitumour efficacy. Median survivals of both ADP-treated groups were significantly longer than the razoxane-treated group. Analysis of the lung metastasis area showed a maximum of 57 per cent for the controls while all treated groups occupied a lesser area. The lowest metastases area was found with the combination treatment BAD + RAZ (18 per cent). This was considered an antimetastatic effect, while ADP treatment effected a time delay only. No change in metastatic pattern was observed in any of the treatment groups. Histological examination showed no effect on the capillaries in the proliferating region of the tumours that could account for the lower occurrence of metastases.


Osteosarcoma Lung Metastasis Phosphonates Lung Area Metastatic Pattern 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Adami, S.,Salvagno, G.,Guarrera, G.,Montesanti, F.,Garavelli, S.,Rosini, S., andLocascio, V., 1986, Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate.Calcified Tissue International, 39, 226–229.PubMedGoogle Scholar
  2. [2]
    Albanese, R., andWatkins, P. A., 1985, The mutagenic activity of razoxane (ICRF 159): an anticancer agent.British Journal of Cancer,52 (5), 725–731.PubMedGoogle Scholar
  3. [3]
    Attardo-Parrinello, G.,Merlini, G.,Pavesi, F.,Crema, F.,Fiorentini, M. L., andAscari, E., 1987, Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis.Archives of International Medicine,147, 1629–1633.Google Scholar
  4. [4]
    Boonekamp, P.,Van Der Wee-Pals, L. J. A.,Van Wijk-Van Lennep, M. M. L.,Wil Thesing, C., andBijvoet, O. L. M., 1986, Two modes of action of bisphophosphonates on osteoclastic resorption of mineralized matrix.Bone and Mineral,1, 27–39.PubMedGoogle Scholar
  5. [5]
    Canfield, R. E., 1987, Rationale for disphosphonate therapy in hypercalcemia of malignancy.American Journal of Medicine,82 (2A), 1–5.Google Scholar
  6. [6]
    Coleman, R. E., andRubens, R. D., 1987, 3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcemia of breast cancer.British Journal of Cancer,56, 465–469.PubMedGoogle Scholar
  7. [7]
    Fischer, V. W.,Wang, G. M., andHobart. N. H., 1986, Mitigation of an anthracycline-induced cardiomyopathy by pretreatment with razoxane: a quantitative morphological assessment.Virchows Archiv,51 (4), 353–361.PubMedGoogle Scholar
  8. [8]
    Gilbert, J. M., 1986, Trials of adjuvant chemotherapy in colorectal cancer.Drugs Experimental Clinical Research,12 (1-3), 201–210.Google Scholar
  9. [9]
    Gilbert, J. M.,Hellmann, K.,Evans, M.,Cassell, P. G.,Taylor, R. H.,Stoodley, B.,Ellis, H., andWastell, C., 1986, Randomized trial of oral adjuvant razoxane (ICRF 159) in resectable colorectal cancer: five year follow up.British Journal of Surgery,73 (6), 446–450.PubMedGoogle Scholar
  10. [10]
    Harinck, H. I. J.,Papapoulos, S. E.,Blanksma, H. J.,Moolenaar, A. J.,Vermeij, P., andBijvoet, O. L. M., 1987, Paget's disease of bone: early and late reponses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). British Medical Journal, 295, 1301–1305.PubMedGoogle Scholar
  11. [11]
    Hellmann, K., 1984, Razoxane. Clinical Chemotherapy, vol. III: Antineoplastic Chemotherapy, edited by H. P. Kuemmerle (New York: Thième Stratton), pp. 275–282.Google Scholar
  12. [12]
    Herman, E.,Witiak, D.,Hellmann, K., andWaravdekar, V., 1982, Biological properties of ICRF-159 and related bis(dioxopiperazine) compounds.Advances in Pharmacology and Chemotherapy,19, 294–298.Google Scholar
  13. [13]
    Kalbfleisch, J. D., andPrentice, R. E., 1980, The Statistical Analysis of Failure Time Data. (New York: Wiley).Google Scholar
  14. [14]
    Klenner, T.,Münch, H.,Schmähl, D., andKeppler, B., 1988, Efficacy of new cisplatin-linked bisphosphonates in transplantable rat osteosarcoma.Journal of Cancer Research and Clinical Oncology, 114, S162.Google Scholar
  15. [15]
    Klenner, T.,Blum, H.,Krempien, B., andSchmähl, D., 1988, Protective effect of 3-disodium-hydroxy-propylidene-1,1-bisphosphonate derivatives in prophylactic treatment of osteolytic bone-lesions induced by Walker carcinosarcoma 256 B in the rat.European Society on Medical Oncology, Abstracts of the 13th Congress,C70, 278(P).Google Scholar
  16. [16]
    Koziol, A. J., andDonna, A. M., 1981, A distribution-free test for tumour growth curve analysis with application to an animal tumour immunotherapy experiment.Biometrics,37, 383–390.PubMedGoogle Scholar
  17. [17]
    Krempien, B.,Wingen, F.,Eichmann, T.,Müller, M., andSchmähl, D., 1988, Protective effects of a prophylactic treatment with the bisphosphonate 3-amino-lhydroxypropane-1,1-bisphosphonic acid on the development of tumor osteopathies in the rat: experimental studies with the Walker carcinosarcoma 256.Oncology,45, 41–46.PubMedGoogle Scholar
  18. [18]
    Löwik, C. W. G. M.,Van Der Pluijm, G., andBijvoet, O. L. M., 1987, Migration and phenotypic transformation of osteoclast-precursors into mature osteoclasts: the effect of dimethyl-APD (Me2APD).Calcified Tissue International,41 (Suppl. 2), 49.Google Scholar
  19. [19]
    Marie, P. J.,Hott, M., andGarba, M., 1985, Inhibition by aminohydroxypropylidene bisphosphonate (AHPrBP) of 1,25(OH)2 vitamin D3-induced stimulated bone turnover in the mouse.Calcified Tissue International,37, 268–275.PubMedGoogle Scholar
  20. [20]
    Metzger, U. F.,Ghosh, B. C., andKisner, D. L., 1985, Adjuvant treatment of colorectal cancer current status and concepts.Cancer Chemotherapy and Pharmacology,14(1), 1–8.PubMedGoogle Scholar
  21. [21]
    Meunier, P. J.,Chapuy, M.,Delmas, P.,Charhon, S.,Edouard, C., andArlot, M., 1987, Intravenous disodium etidronate therapy in Paget's disease of bone and hypercalcemia of malignancy.American Journal of Medicine, 82 (2A), 71–78.PubMedGoogle Scholar
  22. [22]
    Merriman, R. L.,Tanzer, L. R.,Shakelford, K. A.,Bemis, K. G.,Campbell, J. B., andMatsumoto, K., 1988, Inhibition of spontaneous metastasis of Lewis lung carcinoma with a variety of antithrombotic agents does not increase survival.Clinical and Experimental Metastasis,6, (Suppl. 1), p. 98.Google Scholar
  23. [23]
    Papaloulos, S. E.,Aleman, B. M. P.,Hoekman, K.,Löwik, C. W. G. M., andBijvoet, O. L. M., 1987,In vitro assessment of the potency of bisphosphonates can be predictably confirmed in a patient-observer independent clinical model.Calcified Tissue International,41 (Suppl. 2), p. 60.Google Scholar
  24. [24]
    Reitsma, H. P.,Bijvoet, O. L. M.,Potokar, M.,Van Der Wee-Pals, L. J. A., andVan Wijk-Van Lennep, M. M. L., 1983, Apposition and resorption of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).Calcified Tissue International,35, 357–361.PubMedGoogle Scholar
  25. [25]
    Sava, G.,Giraldi, T.,Perissin, L.,Zorzet, S., andDecorti, G., 1987, Effects of antimetastatic, antiinvasive and cytotoxic agents on the growth and spread of transplantable leukemias in mice.Clinical and Experimental Metastasis,5 (1), 27–34.PubMedGoogle Scholar
  26. [26]
    Schenk, R.,Eggli, P.,Fleisch, H., andRosini, S., 1986, Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat.Calcified Tissue International,38, 342–349.PubMedGoogle Scholar
  27. [27]
    Scheulen, M. E., 1985, Kardiotoxische Nebenwirkungen von Zytostatika. Die Anthrazylin-Kardiotoxizität.Münchner Medizinische Wochenschrift,127 (37),862–8666.Google Scholar
  28. [28]
    Scher, H. I., andYagoda, A., 1987, Bone metastasis: Pathogenesis, treatment, and rationale for use of resorption inhibitors.American Journal of Medicine,82 (2A), 6–28.PubMedGoogle Scholar
  29. [29]
    Shinoda, H.,Adamek, G.,Felix, R.,Fleisch, H.,Schenk, R., andHagan, P., 1983, Structure-Activity Relationships of various Bisphosphonates.Calcified Tissue International,35, 87–99.PubMedGoogle Scholar
  30. [30]
    Van Holten-Verzantvoort, A. T.,Bijvoet, O. L. M.,Hermans, J.,Harinck, H. I. J.,Elte, J. W. F.,Beex, L. V. A. M.,Cleton, F. J.,Kroon, H. M.,Vermey, P.,Neijt, J. P., andBiljham, G., 1987, Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment.Lancet,10, 983–985.Google Scholar
  31. [31]
    Wingen, F.,Schmahl, D.,Berger, M. R., andSpring, H., 1984, Intraosseously transplantable osteosarcoma with regularly disseminating pulmonary metastases in rats.Cancer Letters,23, 201–211.PubMedGoogle Scholar
  32. [32]
    Wingen, F.,Eichmann, T.,Manegold, C., andKrempien, B., 1986, Effects of new bisphosphonic acids on tumor-induced bone destruction in the rat.Journal of Cancer Research and Clinical Oncology,111 (1), 35–46.PubMedGoogle Scholar
  33. [33]
    Wingen, F.,Sterz, H.,Blum, H.,Möller, H.,Pittermann, W.,Pool, B. L.,Sinn, H. J.Spring, H., andSchmähl, D., 1986, Synthesis, antitumor activity, distribution and toxicity of 4-[4-bis(2-chloroethyl)amino)phenyl]-1-hydroxybutane-1,1-bisphosphonate (BAD), a new lost derivative with increased accumulation in rat osteosarcoma.Journal of Cancer Research and Clinical Oncology,111, 209–219.PubMedGoogle Scholar
  34. [34]
    Wingen, F., andSchmähl, D., 1987, Pharmakokinetiks of the osteotropic diphosphonate 3-amino-1-hydroxypropane-1,1-diphosphonic acid in mammals.Drug Research,37 (II), 1037–1042.PubMedGoogle Scholar
  35. [35]
    Wingen, F.,Spring, H.,Schm-hl, D., 1987, Antimetastatic effects of razoxane in a rat osteosarcoma model.Clinical and Experimental Metastasis,5, 9–16.PubMedGoogle Scholar

Copyright information

© Taylor & Francis Ltd. 1990

Authors and Affiliations

  • T. Klenner
    • 1
  • F. Wingen
    • 1
  • B. Keppler
    • 2
  • P. Valenzuela-Paz
    • 1
  • F. Amelung
    • 3
  • D. Schmähl
    • 1
  1. 1.Institute of Toxicology and ChemotherapyGerman Cancer Research CenterHeidelbergF.R.G.
  2. 2.Institute of Inorganic ChemistryUniversity of HeidelbergHeidelbergF.R.G.
  3. 3.Institute of Experimental PathologyGerman Cancer Research CenterHeidelbergF.R.G.

Personalised recommendations